Most research compounds trace back to a single enzyme, and 5-Amino-1MQ is no exception. Its story starts not with the molecule itself but with a 2014 observation about fat tissue in overweight mice, and a question that followed: if switching off one enzyme changed how those animals stored fat, could a small molecule do the same thing? The compound that eventually answered that question is 5-amino-1-methylquinolinium, better known by its shorthand, 5-Amino-1MQ.
What is 5-Amino-1MQ?
First, a correction that matters. 5-Amino-1MQ is frequently grouped with research peptides, but it is not a peptide. It is a small synthetic organic molecule, a methylquinolinium salt, built by medicinal chemists rather than assembled from amino acids. Its role is specific: it inhibits an enzyme called nicotinamide N-methyltransferase, usually abbreviated to NNMT. That single function, blocking NNMT, is why the compound exists and why it has drawn research interest at all.
Understanding the history therefore means understanding the enzyme first. Almost everything written about 5-Amino-1MQ is really a story about NNMT and the effort to switch it off.
The enzyme behind the story: NNMT
NNMT sits inside cells and performs a small chemical handoff. It takes a methyl group from S-adenosylmethionine, the body’s universal methyl donor, and attaches it to nicotinamide, a precursor in the NAD+ salvage pathway. The products are 1-methylnicotinamide and S-adenosylhomocysteine. In other words, NNMT consumes two molecules that cells rely on, SAM and the raw material for NAD+, and spends them on a methylation reaction.
For decades NNMT was a footnote. That changed with a study published in Nature in 2014, “Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity” (Kraus et al.). Working in mice, the team used antisense oligonucleotides to lower NNMT specifically in fat tissue and liver. The animals on a high-fat diet gained less weight than controls despite eating the same amount of food. Their adipose SAM and NAD+ levels rose, and markers of cellular energy expenditure went up. The paper reframed NNMT as a possible metabolic target rather than a biochemical curiosity.
From gene knockdown to a molecule (2017–2018)
Knocking a gene down with oligonucleotides is a laboratory technique, not a compound you can characterize like a drug. The obvious next step was to find a small molecule that inhibited the same enzyme. Researchers associated with the University of Texas medical system, including Harshini Neelakantan and colleagues, took up that work in the medicinal chemistry space.
An early scaffold was 1-methylquinolinium, or 1-MQ, which loosely mimics the enzyme’s natural substrate. It inhibited NNMT but left room for improvement. Adding an amino group at the 5 position produced 5-amino-1-methylquinolinium, and this analog was reported to be roughly ten times more potent than the parent 1-MQ while remaining membrane-permeable, an important property since NNMT works inside the cell.
The key publication came in Biochemical Pharmacology: Neelakantan and colleagues, “Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice” (2018, volume 147, pages 141–152). The study reported that administering these NNMT inhibitors to diet-induced obese mice reduced white adipose tissue mass and body weight, shrank fat-cell volume, and lowered plasma triglycerides. A companion paper in Scientific Reports the same year explored related NNMT inhibitors for metabolic disorders. Together, these reports moved 5-Amino-1MQ from an idea into a characterized research compound with published animal data.
Where the research stands now
It is worth being plain about maturity. The evidence base for 5-Amino-1MQ is preclinical. The meaningful results come from cell models and rodent studies, and the mechanism, raising SAM and NAD+ availability by blocking NNMT, is inferred from those systems. As of this writing there is no published human pharmacokinetic study, no completed registered clinical trial, and no regulatory approval for any indication. Claims that reach beyond the mouse and cell data are running ahead of what has actually been shown.
That gap is the honest current state of the history. 5-Amino-1MQ is interesting precisely because it turned a genetic observation into a testable chemical tool in a few short years. Whether that tool translates beyond animal models is an open research question, not a settled one, and the published record is where any serious reading of this compound should stay anchored.
→ 5-Amino-1MQ Research Guide · COA available 5-Amino-1MQ range
Research use only. 5-Amino-1MQ is supplied by Vero Labs strictly as a research compound for in vitro and laboratory use. It is not a dietary supplement, medicine, or clinical product, and is not intended for human or animal use. Every batch is independently third-party lab-tested for identity and purity, with a published Certificate of Analysis (COA) available for the material supplied.